Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study

Publisher： Karger

E-ISSN： 1421-9913|72|3-4|173-180

ISSN： 0014-3022

Source： European Neurology, Vol.72, Iss.3-4, 2014-09, pp. : 173-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients

By  

European Neurology, Vol. 61, Iss. 3, 2009-01 ,pp. : 177-182

Karger

Access to resources Recommend Favorite

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait

By  

Medical Principles and Practice, Vol. 22, Iss. 5, 2013-06 ,pp. : 495-499

Karger

Access to resources Recommend Favorite

Treatment of Relapsing-Remitting Multiple Sclerosis: Current and Future Algorithms

By  

European Neurology, Vol. 72, Iss. 1, 2014-09 ,pp. : 35-38

Karger

Access to resources Recommend Favorite

Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis

By  

European Neurology, Vol. 73, Iss. 3-4, 2015-0 ,pp. : 220-229

Karger

Access to resources Recommend Favorite

Is Interferon Effective and Safe for Relapsing-Remitting Multiple Sclerosis?

By  

Neuroepidemiology, Vol. 21, Iss. 6, 2002-11 ,pp. : 310-

Karger

Access to resources Recommend Favorite